

European Reference Network

for rare or low prevalence complex diseases

Network Neurological Diseases (ERN-RND)

Diagnostic flowcharts for Leukodystrophies

Published by ERN-RND: 11th February 2019

Introduction to the European Reference Network for Rare Neurological Diseases (ERN-RND):

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 32 of Europe's leading expert centres in 13 Member States and includes highly active patient organizations. Centres are located in Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, Slovenia, Spain and the UK.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinsons' Disease
- Dystonia, Paroxysmal Disorder and Neurodegeneration with Brain Ion Accumulation
- Frontotemporal Dementia
- Huntingtons' Disease and other Choreas
- Leukodystrophies

Specific information about the network, the expert centres and the diseases covered can be found at the networks web site www.ern-rnd.eu.

Recommendation for clinical use:

The European Reference Network for Rare Neurological Diseases developed the Diagnostic Flowcharts for Leukodystrophies to help guide the diagnosis of Leukodystrophy patients. The Reference Network recommends the use of these Diagnostic Flowcharts.



Disclaimer:

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service. The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

METHODOLOGY

The development of the Diagnostic Flowcharts for Dystonia was done by the Disease group for Leukodystrophies of ERN-RND.

Disease group for Leukodystrophies:

Disease group coordinators:

Ingeborg Krägeloh-Mann¹; Odile Boespflug-Tanguy²

Disease group members:

Parick Aubourg²; Segolene Ayme²; Enrico Bertini³; Tom de Koning⁴; Maria Teresa Dotti⁵; Antonio Federico⁵; Samuel Gröschel¹; Zoltan Grosz⁶; Thomas Klopstock⁷; Ettore Salsano⁸; Ludger Schöls¹, Caroline Sevin²; Davide Tonduti⁸; Marjo van der Knaap⁹; Nicole Wolf⁹

¹ Universitätsklinikum Tübingen, Germany; ² Assistance Publique-Hôpitaux de Paris, Hôpital Robert-Debré, France: Reference centre for Leukodystrophies; ³ Pediatric hospital Bambino Gesù, Rome, Italy; ⁴ University Medical Center




Groningen, Netherlands; ⁵ AOU Siena, Italy; ⁶ Semmelweis University, Hungary; ⁷ Klinikum der Universität München, Germany,⁸ Foundation IRCCS neurological institute Carlo Besta – Milan, Italy; ⁹ VU University Medical Center Amsterdam, Netherlands.

Flowchart development process:

- Development of flowcharts June 2017– June 2018
- Discussion/Revision in ERN-RND disease group during ERN-RND annual meeting 2018 - 08/06/2018
- Consent on document by whole disease group 02/10/2018



Diagnostic flowchart for Leukodystrophies





A guide to pattern recognition in leukodystrophies

(adapted from Schiffmann and van der Knaap 2009)

Prominent T₂-hyperintensity and prominent T₁-hypointensity relative to gray matter structures = pathologies other than hypomyelination (demyelination and others)

Cerebellum + Middle Diffuse Subcortical Cerebellar Periventricular Large Brain stem Frontal Parieto Temporal Asymmetric Lesions Predominance or Prominence occipital Predominar Cerebral Predominance Predominance Pedundes Predominance Predominance dominance or Prominence HDLS MLC Metachromatic L2-CTX LBSL Alexander Krabbe disease Menkes disease leukodystrophy hydroxyglutaric disease elF-2B-related disorder L2-Peroxisomal LTEL aciduria Metachromatic leukodystrophy Krabbe disease* hydroxyglutaric disorders X-ALD Herpes HBSL Canavan aciduria Alexander disease Laminin alpha-2 deficiency LBSL* Early-onset simplex encephalitis disease ADLD CRMCC Frontal variant *spares arcuate fibers peroxisomal Kearns-Sayre Peroxisomal Mitochondrial diseases of X-ALD disorders Alcardi LBSL Some syndrome disorders Goutières syndrome HDLS mitochondrial Sjogren Larsson syndrome ADLD Neonatal APBD Propionic acidemia defects hypoglycemia Most infectious Aicardi Histiocytosis Congenital CMV Inbom errors of metabolism and inflammatory Wilson Goutières APBD APBD Urea cycle defects Early-onset disease syndrome metabolis including: ODDD maple syrup urine disease disorders RNAse T2 Alexander Laminin alpha-Inborn errors of metabolism (e.g., urea cycle Inborn errors of Molybdenum cofactor Ribose-5disease deficiency 2 deficiency Premutation fragile X metabolism phosphate isomerase Leigh syndrome cotactor deficiency, Glutaric aciduria II, Dihydropterine reductase deficiency, Disorders of branched chain including: Phenylketonuria, FA2H-related disorders, Adenylosuccinati lyase deficiency, Glutaric aciduria type II, Mannosidosis deficiency disorders) syndrome DRPLA Heroin and LTBL Mitochondrial cocaine toxicity leukoencephalopathies FA2H-related branched chain disorders (atrophy) amino acids, Homocystinuria Later-onset Mitochondrial Early-onset neurodegene ve disorders, nerati leukoenceph peroxisomal alopathies disorders including: End stage of Neuronal ceroid-lipofuscinosis, all progressive white matter Niemann Pick C (NB: often early Or may be MULTIFOCAL disease cerebral atrophy) Acquired Progressive (may evolve to confluency) Prominent Perivascular Spaces disorders. Static including: Periventricular leukomalacia, HDLS 18q minus syndrome Mucopolysaccharidoses HIV related APBD Sjogren Larsson Chromosoma encephalopathy abnormalities or genetic L2-hydroxyglutaric aciduria sync mosaicism RNAse T2-deficient LBSL, HBSL leukoencephalopathy Lowe syndrome Urea cycle disorders Congenital CMV PTEN-associated HMG-CoA lyase deficiency disorders Histiocytosis Histiocytosis Disorders of branched chain amino acids Incontinetia pigmenti Vasculopathies (CADASIL, CARASIL, Fabry, Susac syndrome, arteriolosclerosis, vasculitis) Legend Adult polyglucosan body disease Multiple sclerosis ADD: Autosomal dominant leukodystrophy with autonomic symptoms CRMCC: Cerebroretinal microangiopathy with calcifications and cysts CTX: Cerebrotendinous Xanthomatosis Neuromyelitis optica Acute disseminated CTX_Cereorotenonous_Animometosis DRPA.2: Dentatorubo-paikoluvysian atrophy EI/F28-related disorder: Vanishing white matter disease or CACH HDLS: Heredaary diffuse leukoencephalopathy with spheroids/Neuroaxonal leukodystrophy with speroids HSL: Hypomyelination with brain stem and spinal cord and leg involvement encephalomyelitis Progressive multifocal leukoencephalopathy HSSL - hypomyemiation with orban seem and sphale cord and eg involvement TBL: Leukeencephalopathy with thatamic and brain stem involvement and high lactate LBSL: Leukeencephalopathy with prains tem and spinal cordinivolvement and lactate elevation MLC: Megalencephale: leukodystrophy with subcortical cysts. Mitochondrial diseases Subacute sclerosing ODDD: Oculodentodigital dysplasia X-ALD: X-linked adrenoleukodystrophy panencephalitis

May be CONFLUENT

Prominent T₂-hyperintensity and prominent T₁-hypointensity relative to gray matter structures = pathologies other than hypomyelination (demyelination and others)

May be CONFLUENT

Diffuse Cerebral	Periventricular Predominance	Subcorfical Predominance	Large Asymmetric Lesions	Cerebellum + Middle Cerebellar Peduncles Predominance or Prominence	Brain stem Predominance or Prominence	Frontal Predominance	Parieto- occipital Predominance	Temporal Predominance
---------------------	---------------------------------	-----------------------------	--------------------------------	--	---	-------------------------	---------------------------------------	--------------------------



This document was supported by and done in the framework of the European Reference Network for Rare Neurological Diseases (ERN-RND). ERN-RND is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Commission (ERN-RND: 3HP 767231).

C	r may be MULTIFOCAL	
Progressive (may evolve confluency)	o Static	Prominent Perivascular Spaces

Some of the differences with the original diagnostic flowchart by Schiffmann et al. include the following:

ERN-RND flowchart	Schiffmann, van der Knaap flowchart
"may be" confluent or "may be" multifocal	Confluent or multifocal
May be confluent: large asymmetric lesions	NA
May be confluent: temporal predominance	NA
"may be multifocal", 3 sub-categories: progressive, static and prominent perivascular spaces	Multifocal, no sub-categories
NA	Hypomyelination: typical PNS involvement or no typical PNS involvement

References:

Schiffmann R, van der Knaap MS (2009) An MRI-based approach to the diagnosis of white matter disorders, Neurology 72(8): 750–759.



ABBREVIATIONS

ADP6: adult polyglucosan body disease

ADLD: autosomal dominant leukodystrophy with autonomic symptoms

CRMCC: cerebroretinal microangiopathy w/calcifications & cysts

CTX: cerebrotendinous xanthomatosis

DRPLA: dentatorubropallidoluysian atrophy

ElF2B-related disorder: vanishing white matter disease or CACH

HDLS: hereditary diffuse leukoencephalopathy with spheroids

HBSL: hypomyelination with brainstem and spinal cord involvement and leg spasticity

LTBL: leukoencephalopathy with thalamus and brainstem involvement and high lactate

LBSL: leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation

MLC: megalencephalic Leukoencephalopathy with subcortical cysts

ODDD: oculodentodigital dysplasia

X-ALD: x-linked adrenoleukodystrophy

